ADHD attention-deficit/hyperactivity disorder
Conditions
Interventions
The children in the control arm will have a gradual titration of
methylphenidate, according to the protocol of the participating centers.
The children in the placebo-controlled double-blind titratio
ADHD
methylphenidate
randomized controlled trial
Sponsors
Vrije Universiteit
Eligibility
Age
2 Years to 17 Years
Inclusion criteria
Inclusion criteria: children between the age of 6 and 12 with a DSM-based ADHD diagnosis, with a clinical indication to start pharmacological therapy with short-acting methylphenidate
Exclusion criteria
Exclusion criteria: - counter-indication for the start-up of methylphenidate (e.g. cardiac problems) - treated with MPH in the last 4 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measures are: -number of placebo and non-responders detected -ADHD symptoms measured with questionnaires -side effects measured with questionnaires | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome measures are: -satisfaction of parents, teachers and therapists on the titration method -symptoms of CD and ODD, social-emotional functioning | — |
Countries
The Netherlands
Outcome results
None listed